- Current report filing (8-K)
27 11월 2008 - 6:50AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported):
November
22, 2008
Targeted
Genetics Corporation
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Washington
|
|
0-23930
|
|
91-1549568
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
1100
Olive Way, Suite 100, Seattle, Washington
|
|
98101
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
|
|
(206) 623-7612
|
Not
Applicable
(Former
name or former address if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item
1.01. Entry into a Material Definitive Agreement.
On
November 14, 2008, Targeted Genetics Corporation executed a Separation Agreement
and Release, or Separation Agreement, with H. Stewart Parker which became
effective on November 22, 2008. Ms. Parker resigned from her position as the
chief executive officer and president of Targeted Genetics effective November
6,
2008, as described in the Company’s Form 8-K filed on November 12, 2008 and
resigned from the Board of Directors of Targeted Genetics on November 20, 2008
as described in the Company’s Form 8-K filed on November 20, 2008.
Pursuant
to the terms of the Separation Agreement, Ms. Parker’s 83,334 unvested
restricted stock units previously issued to her pursuant to Targeted Genetics’
Stock Incentive Plan were accelerated to fully vest upon effectiveness of the
Separation Agreement, Ms. Parker was granted an additional 150,000 shares of
common stock, the Company will provide continuation of Ms. Parker’s health
insurance coverage for six months and the Company will reimburse Ms. Parker
for
certain expenses as set forth in the Separation Agreement. The Separation
Agreement also provides for Ms. Parker to provide consulting services to the
Company for $5,000 per month for a period of six months.
The
foregoing description of the Separation Agreement is qualified in its entirety
by reference to the Separation Agreement and Release attached hereto as Exhibit
10.1 to this current report and incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibit:
10.1
Separation
Agreement and Release dated November 14, 2008 between Targeted Genetics and
H.
Stewart Parker
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
TARGETED
GENETICS CORPORATION
|
|
|
|
Dated:
November 26, 2008
|
By:
|
/s/
DAVID J. POSTON
|
|
David
J. Poston
Vice
President Finance and Chief Financial
Officer
|
INDEX
TO EXHIBITS
Exhibit
Number
|
Description
|
|
|
10.1
|
Separation
Agreement and Release dated November 14, 2008 between Targeted Genetics
and
H. Stewart Parker
|
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024